Medical equipment manufacturer Xylyx Bio, Inc. announced on Monday that it has received a USD2.45m Small Business Innovation Research (SBIR) grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) to advance its InMatrico platform for liver fibrosis drug testing.
This platform aims to improve the discovery and testing of drug candidates for liver fibrosis, a process linked to several chronic liver diseases, including alcohol-associated and metabolic dysfunction-associated steatotic liver diseases.
With MASLD affecting 100 million people in the US and limited efficacy from approved treatments, there is a critical need for better drug testing models. InMatrico integrates patient-derived fibrotic liver extracellular matrix and key liver cells to address this gap. The award will support the platform's further development, enhancing drug discovery for fibrotic liver disease.
Xylyx Bio receives SBIR grant from NIDDK
Lilly expands manufacturing footprint in Ireland
Arecor reports positive Phase I Results for AT278 insulin at EASD 2024
Diamyd Medical seeks Fast-Track approval for Type 1 Diabetes immunotherapy
Biosergen completes first successful BSG005 treatment in invasive fungal trial
Hyundai Bioscience to conduct Phase 3 trial for high-risk COVID-19 patients
RedHill Biopharma's Opaganib receives US FDA orphan-drug designation
Lifecare sensor achieves 9-week longevity in dog trial
RedHill Biopharma reports promising results for opaganib in obesity and diabetes studies
Sumitomo Pharma and Poxel report positive results from TWYMEEG study in Japan
Sapphiros names new chief financial officer
Amylyx receives EU Orphan Drug Designation for Wolfram syndrome treatment
KVK Tech registers Lomaira 8mg tablets in Mexico
GSK's Arexvy receives positive CHMP opinion for at-risk adults aged 50-59
M8 Pharmaceuticals signs exclusive licensing and distribution agreement with LG Chem